Monte Rosa Therapeutics, Inc. (GLUE): Cash & Equivalents
$129.88M
As of 2025-12-31
$90.10M
As of 2026-06-30
+33.2%
3-year compound annual growth
+25.5%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $129.88M | -42.1% | 2026-03-17, Balance as of period end |
| 2024-12-31 | $224.25M | +75.1% | 2026-03-17, Balance as of period end |
| 2023-12-31 | $128.10M | +133.3% | 2025-03-20, Balance as of period end |
| 2022-12-31 | $54.91M | -84.1% | 2024-03-14, Balance as of period end |
| 2021-12-31 | $346.07M | +729.9% | 2023-03-16, Balance as of period end |
| 2020-12-31 | $41.70M | n/a | 2022-03-29, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Monte Rosa Therapeutics, Inc. (GLUE) | 2025-12-31 | $129.88M | -42.1% |
| Atara Biotherapeutics, Inc. (ATRA) | 2025-12-31 | $8.48M | -66.1% |
| Agenus Inc (AGEN) | 2025-12-31 | $3.00M | -92.6% |
| ImmunityBio, Inc. (IBRX) | 2025-12-31 | $88.33M | -38.4% |
| Beam Therapeutics Inc. (BEAM) | 2025-12-31 | $294.94M | +4.6% |
| Century Therapeutics, Inc. (IPSC) | 2025-12-31 | $61.85M | +5.8% |
| Sutro Biopharma, Inc. (STRO) | 2025-12-31 | $58.13M | -69.5% |
| Ginkgo Bioworks Holdings, Inc. (DNA) | 2025-12-31 | $167.20M | -70.2% |
| REGENXBIO Inc. (RGNX) | 2025-12-31 | $34.47M | -40.1% |
Compare GLUE, ATRA, AGEN, IBRX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗